Synchron has announced positive results from its COMMAND study, which evaluated the safety and efficacy of its Stentrode brain-computer interface (BCI) device in six patients over a year.

The trial successfully met its primary endpoint, confirming that there were no device-related deaths or serious disabilities among participants during the one-year evaluation period.

Throughout the first year of the U.S. clinical trial, there were no serious adverse effects reported, indicating a strong safety profile for the BCI.

The study demonstrated that brain signals related to motor intent could be consistently captured and converted into Digital Motor Outputs (DMOs), allowing users to perform various digital tasks.

The Stentrode BCI is implanted in a blood vessel near the brain's motor cortex through a minimally invasive endovascular procedure, enabling users to control devices using only their thoughts.

All six patients in the trial achieved accurate deployment of the device, with successful coverage of the target motor cortex.

This innovative technology primarily aims to help individuals with severe paralysis regain functional independence and control over digital devices.

Looking ahead, Synchron plans to enroll dozens of participants in future trials to further enhance the BCI technology and its applications.

Data presented at the 2024 Congress of Neurological Surgeons confirmed that no serious adverse events related to the device were reported in either the U.S. or previous Australian trials.

Concerns regarding accidental activation of the BCI during sleep are being addressed through ongoing research to improve user experience.

The integration of the BCI with devices like Apple Vision Pro provides an alternative to traditional controls, making technology more accessible for users without hand function.

Synchron has launched a patient registry to connect with individuals interested in participating in upcoming clinical trials, as it prepares for the next phase of research.